Manufacturing Misery in Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Misery in Vaccines
Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.


Pharmaceutical Technology Europe


References

1. L. Galambos, What are the Prospects for a New Golden Era in Vaccines? (UK Vaccines Group, UK, 2008).

2. Pharmaletter website, "Novartis' flu vaccines suspended in several countries on suspected quality issues", http://www.thepharmaletter.com/, accessed 12 Dec., 2012.

3. Fiercepharma website, "Italy bans Novartis vaccines even after company assures their safety", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

4. Reuters website, "France halts sale of Novartis flu vaccine", http://uk.reuters.com/, accessed 12 Dec., 2012.

5. Deutsche Welle website, "Germany moves to cut off vaccine shortage", http://www.dw.de/, accessed 12 Dec., 2012.

6. The Globe and Mail website, "Canada suspends distribution of Novartis flu shots", http://www.theglobeandmail.com/, accessed 12 Dec., 2012.

7. Fiercepharma website, "Novartis plant delay, vaccine woes steal spotlight", http://www.fiercepharma.com/, accessed 12 Dec., 2012.

8. Health Canada website, "Health Canada Endorsed Important Safety Information on Infanrix Hexa", http://www.hc-sc.gc.ca/, accessed 12 Dec., 2012.

9. In-pharmatechnologist website, "GSK pulls vaccine batch in Canada over contamination concerns", http://www.in-pharmatechnologist.com/, accessed 12 Dec., 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here